Real-World Patient Outcomes With Elinzanetant: Perspective from Genevieve Neal-Perry, MD, PhD

The treatment landscape for vasomotor symptoms (VMS) during menopause is evolving, with neurokinin receptor antagonists offering a rapidly effective nonhormonal option for patients who cannot or prefer not to use hormone therapy. On October 24, 2025, the US FDA approved elinzanetant 60 mg capsules (Lynkuet; Bayer) as the first dual NK-1/NK-3 antagonist for the treatment of moderate-to-severe VMS associated with menopause.¹

The approval was based on the phase 3 clinical program (OASIS 1, 2 and 3) which enrolled post-menopausal women aged 40-65 years experiencing moderate to severe VMS. In OASIS 1/2, women received once-daily oral elinzanetant 120 mg or placebo for 26 weeks; key endpoints included mean change in frequency and severity of VMS at weeks 4 and 12. OASIS 3, a 52-week double-blind randomized study (n = 628), confirmed sustained reductions in VMS frequency along with improvements in sleep disturbances and menopause-related quality of life. A recent meta-analysis found that elinzanetant significantly reduced the frequency of VMS compared with placebo (mean difference –23.1 episodes; 95 % CI –24.2 to –22.0) and improved intensity and sleep disturbance scores.^2,3

At the American College of Obstetricians and Gynecologists (ACOG) 2026 Annual Clinical and Scientific Meeting, Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant and identified which patients are ideal candidates.

“Patients are responding very well and very similarly to what we saw in the trials,” Neal-Perry said, pointing to rapid reductions in hot flashes and improvements in sleep. Watch the video above for more.

Check out all the Patient Care ACOG 2026 coverage.

References:

1. Bayer’s Lynkuet (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause. News release. Bayer. October 24, 2025. Accessed October 24, 2025. https://www.bayer.com/media/en-us/bayers-lynkuet-elinzanetant-approved-in-the-us-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause/
2. Halsey G. Menopausal VMS Severity, Frequency Reduced Significantly with Elinzanetant: Bayer Shares Data from Pivotal OASIS 1 and 2 Trials. Patient Care Online. Published May 17, 2024. Accessed May 2, 2026. https://www.patientcareonline.com/view/menopausal-vms-severity-frequency-reduced-significantly-with-elinzanetant-bayer-shares-data-from-pivotal-oasis-1-and-2-trials
3. Panay N, Joffe H, Maki PM, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA Intern Med. Published online September 08, 2025. doi:10.1001/jamainternmed.2025.4421